Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the period of October 2021, specifically dated October 12, 2021. The filing reports on a significant clinical milestone for the Company's lead candidate, vilobelimab, in the treatment of severe COVID-19.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements or operational financial data.
Material Changes and Clinical Progress
- Phase III Enrollment Complete: The Company completed enrollment for the Phase III portion of its Phase II/III study in severe COVID-19. The study enrolled 369 mechanically ventilated patients across the EU, South America, and other regions.
- Study Design: Patients were randomized 1:1 to receive vilobelimab or placebo, with all receiving standard of care. The primary endpoint is 28-day all-cause mortality.
- Phase II Results: The preceding Phase II part enrolled 30 patients. The 28-day all-cause mortality rate was 13% (2 of 15) in the vilobelimab arm compared to 27% (4 of 15) in the best supportive care arm.
- Secondary Observations: The vilobelimab arm showed fewer instances of renal impairment, more reversal of blood lymphocytopenia, and greater lowering of lactate dehydrogenase concentrations compared to the control arm. A temporary, statistically significant increase in D-dimer levels was noted, potentially signaling blood clot lysis.
Outlook and Management Commentary
Treatment in the Phase III study is ongoing. Topline results are expected to be available in the first quarter of 2022. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard clinical trial uncertainties implied by the ongoing nature of the study.
Key Facts for Investor Verification
- Verify the expected timeline for topline results (Q1 2022) and any potential delays.
- Confirm the statistical significance of the Phase II mortality reduction (13% vs 27%) in the context of the small sample size (n=30).
- Monitor the safety profile regarding the observed increase in D-dimer levels during the Phase III trial.
- Review the Company's cash runway and capital requirements, as this filing does not disclose current liquidity or burn rate.